Onxeo S.A (CPH:ONXEO) (Paris:ONXEO), a clinical-stage biotechnology company, announced on Monday the publication of its shareholder letter.
According to the company, in this new issue, readers will find out about Onxeo's perspectives for 2020 and the clinical development plan of AsiDNA, notably about an upcoming clinical study designed to evaluate the effect of AsiDNA in combination with niraparib on the abrogation of tumour resistance to this PARP inhibitor, approved as a second d line maintenance therapy for recurrent ovarian cancer.
Onxeo develops innovative oncology drugs targeting tumour DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR).
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates